TABLE 2

Baseline characteristics by categories of change in ADO (age, dyspnoea, airflow obstruction) score per year groups among the 4804 included patients with three or more ADO measurements

Improving
ADO change
Stable
ADO change
Worsening
ADO change
Subjects1883766850
Age years69.6±9.568.8±9.269.2±9.5
Dyspnoea (mMRC score)1.44 (0.97)1.94 (1.04)1.23 (0.97)
 09 (4.8)613 (16.3)237 (27.9)
 171 (37.8)1547 (41.1)265 (31.2)
 240 (21.3)1016 (27.0)267 (31.4)
 358 (30.9)533 (14.2)75 (8.8)
 410 (5.3)57 (1.5)6 (0.7)
FEV1 % pred47.6±15.058.6±19.164.9±21.3
First ADO score8.9±1.97.6±2.06.6±2.0
 0–57 (3.7)543 (14.4)239 (28.1)
 6 or 733 (17.6)1262 (33.5)333 (39.2)
 8 or 977 (41.0)1355 (36.0)230 (27.1)
 10–1471 (37.8)606 (16.1)48 (5.7)
Four or more ADO measurements32 (17.0)1146 (30.4)233 (27.4)
Female96 (51.1)1676 (44.5)379 (44.6)
White ethnicity99 (100.0)1848 (98.4)426 (98.2)
Townsend deprivation quintile
 1 (least deprived)27 (14.6)643 (17.4)145 (17.3)
 237 (20.0)692 (18.8)151 (18.0)
 341 (22.2)805 (21.8)186 (22.2)
 443 (23.2)820 (22.3)195 (23.3)
 5 (most deprived)37 (20.0)726 (19.7)161 (19.2)
Smoking status
 Current smoker49 (26.9)994 (28.1)258 (32.0)
 Ex-smoker104 (57.1)2066 (58.4)468 (58.0)
 Never-smoker29 (15.9)478 (13.5)81 (10.0)
BMI kg·m−228.3±6.327.5±5.526.9±5.6
BMI category
 Underweight7 (3.9)90 (2.5)27 (3.3)
 Normal50 (27.9)1130 (31.8)300 (36.9)
 Overweight70 (39.1)1324 (37.3)281 (34.5)
 Obese52 (29.1)1005 (28.3)206 (25.3)
LAMA prescription66 (35.1)1000 (26.6)266 (31.3)
LABA prescription53 (28.2)1165 (30.9)259 (30.5)
SAMA prescription31 (16.5)603 (16.0)143 (16.8)
SABA prescription118 (62.8)2212 (58.7)518 (60.9)
ICS-containing prescription52 (27.7)1306 (34.7)287 (33.8)
Pulmonary rehabilitation referral6 (3.2)176 (4.7)29 (3.4)
Heart failure11 (5.9)192 (5.1)42 (4.9)
Ischaemic heart disease37 (19.7)716 (19.0)181 (21.3)
Anxiety7 (3.7)86 (2.3)16 (1.9)
Depression12 (6.4)238 (6.3)55 (6.5)
Diabetes28 (14.9)469 (12.5)96 (11.3)
TIA, stroke or PAD25 (13.3)443 (11.8)121 (14.2)
Asthma68 (36.2)1351 (35.9)311 (36.6)

Data are presented as n, mean±sd or n (%). mMRC: modified Medical Research Council; FEV1: forced expiratory volume in 1 s; BMI: body mass index; LAMA: long-acting muscarinic antagonist; LABA: long-acting β2-agonist; SAMA: short-acting muscarinic antagonist; SABA: short-acting β2-agonist; ICS: inhaled corticosteroid; TIA: transient ischaemic attack; PAD: peripheral artery disease.